Premium
Clinical Trial of SE 505 … A New Oxytocic Mixture
Author(s) -
Barbaro C. A.,
Smith G. O.
Publication year - 1961
Publication title -
australian and new zealand journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.734
H-Index - 65
eISSN - 1479-828X
pISSN - 0004-8666
DOI - 10.1111/j.1479-828x.1961.tb00551.x
Subject(s) - ergometrine , oxytocin , medicine , intramuscular injection , anesthesia , postpartum haemorrhage , placenta , fetus , obstetrics , pregnancy , biology , genetics
Summary A clinical trial has been conducted using SE 505, a new oxytocin: ergometrine mixture. Administration was by intramuscular injection after delivery of the foetus. Comparing the results obtained in a similar group of patients given ergometrine by intravenous injection after delivery of the foetus and ergometrine by intramuscular injection after delivery of the placenta, the new Compound was found to be associated with a significantly greater postpartum haemorrhage rate and mean blood loss.